Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. grew its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 7.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 279,682 shares of the company’s stock after purchasing an additional 19,562 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Keros Therapeutics were worth $4,427,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Exchange Traded Concepts LLC bought a new position in Keros Therapeutics in the 4th quarter valued at about $99,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Keros Therapeutics by 19.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company’s stock worth $136,000 after acquiring an additional 1,372 shares during the period. Handelsbanken Fonder AB boosted its holdings in shares of Keros Therapeutics by 11.3% in the fourth quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company’s stock valued at $171,000 after acquiring an additional 1,100 shares in the last quarter. Victory Capital Management Inc. bought a new position in shares of Keros Therapeutics in the third quarter valued at approximately $216,000. Finally, Point72 Asia Singapore Pte. Ltd. increased its stake in shares of Keros Therapeutics by 36.7% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,844 shares of the company’s stock valued at $223,000 after acquiring an additional 1,033 shares during the period. 71.56% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have issued reports on KROS. BTIG Research lowered Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, December 12th. Cantor Fitzgerald lowered Keros Therapeutics from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 21st. William Blair downgraded shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Guggenheim reaffirmed a “neutral” rating on shares of Keros Therapeutics in a research note on Friday, January 17th. Finally, Wedbush cut shares of Keros Therapeutics from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $47.00 to $15.00 in a report on Friday, January 17th. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $42.33.

Keros Therapeutics Stock Performance

Shares of NASDAQ:KROS opened at $11.29 on Wednesday. The firm has a 50 day simple moving average of $11.13 and a 200 day simple moving average of $35.22. Keros Therapeutics, Inc. has a 52 week low of $9.78 and a 52 week high of $72.37. The company has a market cap of $457.94 million, a PE ratio of -2.17 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.36) by $0.22. The company had revenue of $3.04 million during the quarter, compared to analyst estimates of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. On average, equities analysts predict that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.